Clinical trials: Low Ferritin
Myelodysplastic Syndrome, Iron Overload
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
- Trial name
- NCT00110266
- Testing
- Deferasirox
- Where
- 48 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Novartis Pharmaceuticals
Iron Deficiency (Without Anemia)
Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels
This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting…
- Trial name
- NCT05257343
- Testing
- Liquid Iron Supplement (Blood Builder ®)
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Myelodysplastic Syndromes, Transfusion Dependent Iron Overload
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
The purpose of this study is to investigate the effects of iron chelation using deferasirox in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS patients who show signs of iron overload due…
- Trial name
- NCT00481143
- Testing
- ICL670/Deferasirox
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals